Rita P. Dalal

2.6k total citations
21 papers, 622 citations indexed

About

Rita P. Dalal is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Rita P. Dalal has authored 21 papers receiving a total of 622 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 4 papers in Surgery. Recurrent topics in Rita P. Dalal's work include Cancer Immunotherapy and Biomarkers (7 papers), HER2/EGFR in Cancer Research (6 papers) and Gastric Cancer Management and Outcomes (6 papers). Rita P. Dalal is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), HER2/EGFR in Cancer Research (6 papers) and Gastric Cancer Management and Outcomes (6 papers). Rita P. Dalal collaborates with scholars based in United States, Japan and Spain. Rita P. Dalal's co-authors include Charles S. Fuchs, Toshihiko Doi, Talia Golan, Jiangdian Wang, Zev A. Wainberg, Kei Muro, Shadia I. Jalal, Daniel V.T. Catenacci, Yung‐Jue Bang and Harry H. Yoon and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Cancer Research.

In The Last Decade

Rita P. Dalal

20 papers receiving 613 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rita P. Dalal United States	10	415	311	144	109	103	21	622
Fabiola Lorena Rojas Llimpe Italy	10	500 1.2×	498 1.6×	217 1.5×	52 0.5×	135 1.3×	32	791
Daniel Virgil Thomas Catenacci United States	11	365 0.9×	271 0.9×	167 1.2×	42 0.4×	74 0.7×	19	524
Yuichi Mikamoto Japan	7	688 1.7×	318 1.0×	196 1.4×	147 1.3×	127 1.2×	10	852
Hitomi Tamura Japan	6	553 1.3×	199 0.6×	145 1.0×	109 1.0×	74 0.7×	11	661
Quanren Wang China	1	245 0.6×	148 0.5×	61 0.4×	67 0.6×	26 0.3×	2	368
David E. Adelberg United States	13	317 0.8×	305 1.0×	170 1.2×	38 0.3×	106 1.0×	37	542
KIKUO KOUFUJI Japan	14	162 0.4×	358 1.2×	261 1.8×	73 0.7×	123 1.2×	79	657
Jiangdian Wang United States	8	671 1.6×	409 1.3×	273 1.9×	174 1.6×	142 1.4×	11	860
Holly Kemberling United States	7	471 1.1×	154 0.5×	125 0.9×	99 0.9×	23 0.2×	9	567
Lilian Bu China	7	356 0.9×	450 1.4×	117 0.8×	16 0.1×	94 0.9×	11	552

Countries citing papers authored by Rita P. Dalal

Since Specialization

Citations

This map shows the geographic impact of Rita P. Dalal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rita P. Dalal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rita P. Dalal more than expected).

Fields of papers citing papers by Rita P. Dalal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rita P. Dalal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rita P. Dalal. The network helps show where Rita P. Dalal may publish in the future.

Co-authorship network of co-authors of Rita P. Dalal

This figure shows the co-authorship network connecting the top 25 collaborators of Rita P. Dalal. A scholar is included among the top collaborators of Rita P. Dalal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rita P. Dalal. Rita P. Dalal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vaishampayan, Ulka N., Jameel Muzaffar, Ira Winer, et al.. (2024). Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1). Journal for ImmunoTherapy of Cancer. 12(11). e010143–e010143. 14 indexed citations

Piha‐Paul, Sarina A., Justin Call, Alexander I. Spira, et al.. (2023). 744 Assessment of safety and immunologic activity of nemvaleukin alfa in patients with advanced solid tumors treated with less frequent intravenous dosing (ARTISTRY-3). SHILAP Revista de lepidopterología. A839–A840. 1 indexed citations

Vaishampayan, Ulka N., Shipra Gandhi, Anna Spreafico, et al.. (2022). Nemvaleukin alfa combination therapy for gastrointestinal (GI) cancers: Preclinical evidence and clinical data from the ARTISTRY-1 trial.. Journal of Clinical Oncology. 40(4_suppl). 659–659.

Calvo, Emiliano, Valentina Boni, Arvind Chaudhry, et al.. (2022). Nemvaleukin alfa in patients with advanced renal cell carcinoma: ARTISTRY-1.. Journal of Clinical Oncology. 40(6_suppl). 330–330. 2 indexed citations

Herzog, Thomas J., John L. Hays, Kathleen N. Moore, et al.. (2022). TP025/#1399 Artistry-7: phase 3 multicenter study of nemvaleukin alfa plus pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. A235.2–A235. 1 indexed citations

Camidge, D. Ross, Filip Jankú, Alejandro Martínez‐Bueno, et al.. (2020). Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in advanced non-small cell lung cancer (NSCLC) patients with MET amplification/exon 14 deletion (MET^Amp/Ex14∆).. Journal of Clinical Oncology. 38(15_suppl). 9510–9510. 28 indexed citations

Bang, Yung‐Jue, Yoon‐Koo Kang, Daniel V.T. Catenacci, et al.. (2019). Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. Gastric Cancer. 22(4). 828–837. 189 indexed citations

Yamaguchi, Kensei, Yung‐Jue Bang, Daisuke Sakai, et al.. (2018). A randomized phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer.. Journal of Clinical Oncology. 36(15_suppl). TPS4133–TPS4133. 3 indexed citations

Reck, Martin, Edward B. Garon, Luis Paz‐Ares, et al.. (2017). Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non–Small-Cell Lung Cancer (RELAY): Phase Ib Results. Clinical Lung Cancer. 19(3). 213–220.e4. 12 indexed citations

10.

Nakagawa, Kazuhiko, Luis Paz‐Ares, Santiago Ponce, et al.. (2017). OA11.02 Randomized Phase 1b/3 Study of Erlotinib plus Ramucirumab in First-Line EGFR Mut + Stage IV NSCLC: Phase 1b Safety Results. Journal of Thoracic Oncology. 12(1). S285–S285. 1 indexed citations

11.

Doi, Toshihiko, Jaafar Bennouna, Lin Shen, et al.. (2017). Pembrolizumab versus investigator’s choice single-agent chemotherapy in patients with advanced/metastatic esophageal adenocarcinoma that progressed after first-line therapy: Phase 3 KEYNOTE-181 study. Annals of Oncology. 28. iii33–iii33. 2 indexed citations

12.

Vahdat, Linda T., Rachel M. Layman, Denise A. Yardley, et al.. (2017). Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer. The Oncologist. 22(3). 245–254. 21 indexed citations

13.

Fuchs, Charles S., Toshihiko Doi, Raymond Woo-Jun Jang, et al.. (2017). KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer.. Journal of Clinical Oncology. 35(15_suppl). 4003–4003. 127 indexed citations

14.

Bang, Yung‐Jue, Kei Muro, Charles S. Fuchs, et al.. (2017). KEYNOTE-059 cohort 2: Safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer.. Journal of Clinical Oncology. 35(15_suppl). 4012–4012. 52 indexed citations

15.

Masuda, Norikazu, Hiroji Iwata, Kenjiro Aogi, et al.. (2016). Safety and pharmacokinetics of ramucirumab in combination with docetaxel in Japanese patients with locally advanced or metastatic breast cancer: a Phase Ib study. Japanese Journal of Clinical Oncology. 46(12). 1088–1094. 6 indexed citations

16.

Garon, Edward B., Martin Reck, Luis Paz‐Ares, et al.. (2016). Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 18(1). 96–99. 9 indexed citations

17.

Fuchs, Charles S., Atsushi Ohtsu, Josep Tabernero, et al.. (2016). Preliminary safety data from KEYNOTE-059: Pembrolizumab plus 5-fluorouracil (5-FU) and cisplatin for first-line treatment of advanced gastric cancer.. Journal of Clinical Oncology. 34(15_suppl). 4037–4037. 13 indexed citations

18.

Overman, Michael J., Charles D. Lopez, Al B. Benson, et al.. (2016). A randomized phase 2 study of the Bruton tyrosine kinase (Btk) inhibitor acalabrutinib alone or with pembrolizumab for metastatic pancreatic cancer (mPC).. Journal of Clinical Oncology. 34(15_suppl). 4130–4130. 15 indexed citations

19.

Zhu, Andrew X., Richard S. Finn, Mary F. Mulcahy, et al.. (2013). A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer. Clinical Cancer Research. 19(23). 6614–6623. 122 indexed citations

20.

Dalal, Rita P., et al.. (2012). R. K. Narayan's moral vision with special reference to the guide. International Conference on Bioinformatics. 2(7). 220–225. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact